Immunogenicity and Reactogenicity Following 2- and 3-Dose SARS-CoV-2 Vaccination in Persons With HIV
J Acquir Immune Defic Syndr
.
2023 Jan 1;92(1):e3-e6.
doi: 10.1097/QAI.0000000000003112.
Authors
Mayan S Teles
1
,
Stephanie Lushniak
1
,
Teresa Po-Yu Chiang
1
,
Justin R Bailey
2
,
Kelly A Gebo
2
3
,
Andrew H Karaba
2
,
Christine M Durand
2
,
Dorry L Segev
1
3
4
,
Caoilfhionn M Connolly
5
,
William A Werbel
2
Affiliations
1
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
2
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
3
Department of Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD.
4
Department of Surgery, NYU Grossman School of Medicine, New York, NY; and.
5
Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.
PMID:
36476571
PMCID:
PMC9743179
DOI:
10.1097/QAI.0000000000003112
No abstract available
MeSH terms
COVID-19 Vaccines / adverse effects
COVID-19* / prevention & control
HIV Infections* / drug therapy
Humans
SARS-CoV-2
Substances
COVID-19 Vaccines
Grants and funding
P30 AI094189/AI/NIAID NIH HHS/United States
U01 AI138897/AI/NIAID NIH HHS/United States
K23 AI157893/AI/NIAID NIH HHS/United States
U01 AI134591/AI/NIAID NIH HHS/United States
K24 AI144954/AI/NIAID NIH HHS/United States
K08 AI156021/AI/NIAID NIH HHS/United States